Key result
Hydroxytyrosol reduces saphenous vein intimal thickness by ~44% while preserving endothelial function.
Why the study?
Venous intimal hyperplasia compromises long-term CABG graft patency, and antiproliferative drugs that impair endothelial cell function can exacerbate this process. This study investigated whether the olive oil derivative hydroxytyrosol could inhibit smooth muscle cell proliferation without compromising endothelial cell homeostasis.
Does hydroxytyrosol attenuate venous intimal hyperplasia and smooth muscle cell proliferation without impairing endothelial cell homeostasis in human saphenous vein in vitro and ex vivo models?
Does hydroxytyrosol attenuate venous intimal hyperplasia and smooth muscle cell proliferation without impairing endothelial cell homeostasis in human saphenous vein in vitro and ex vivo models?
Hydroxytyrosol selectively inhibits vascular smooth muscle cell proliferation and intimal thickening while preserving endothelial cell homeostasis at 50 μM via differential Akt and Nrf2/HO-1 modulation, supporting its preclinical potential to prevent saphenous vein graft failure.
Answers are grounded in this paper and cite their sources.
Supports selective SMC inhibition in human vein grafts; leaves open clinical translation for patency.
Background : Venous intimal hyperplasia (VIH) contributes to luminal vascular thickening, which compromises the long-term patency of coronary artery bypass grafting (CABG) grafts and negatively impacts the outcomes of percutaneous coronary intervention. Antiproliferative drugs that impair endothelial cell (EC) function can exacerbate VIH. Additionally, endothelial dysfunction leads to an imbalance in reactive oxygen species, further inducing excessive vascular remodelling. Hydroxytyrosol (HT), an olive oil derivative, has been proved to exert antioxidant, anti-inflammatory, and antiproliferative effects. We hypothesize that HT could inhibit smooth muscle cell (SMC) proliferation without compromising EC homeostasis, thus emerging as an adjuvant solution to prevent intimal hyperplasia in patients undergoing CABG. Methods & Results : Dose-response experiments of HT were conducted in vitro on ECs and PDGF-BB-stimulated SMCs. In vitro , HT at concentrations ranging from 40 μM to 320 μM, significantly inhibited PDGF-induced SMC proliferation, migration, and chemotaxis via downregulating Akt pathway. In contrast, HT concentrations below 50 μM preserved EC viability, proliferation, and migration. Additionally, HT activated the Nrf2/HO-1 antioxidant pathway in both cell types. Therefore, HT at 50uM was then tested in an ex vivo human saphenous vein (hSV) ring culture. In the ex vivo hSV model, a significant increase in cellular proliferation was observed from day 0 to day 21. HT treatment reduced intimal thickness by 44% and SMC proliferation by 53% (p=0.004), likely due to the inhibition of Akt and vimentin, along with the HO-1 activation. Conclusions : Our findings underscore the therapeutic potential of HT in preventing intimal hyperplasia as per its balanced effects on regulating the biological function of vessel resident cells. Further research is warranted to evaluate HT’s effect on reendothelialization, particularly using 3D disease models or animal studies.
No takes yet. Share an insight, caveat, or question.
Vijakumaran et al. (2026) studied Venous intimal hyperplasia in human saphenous vein grafts (n=8). Hydroxytyrosol vs. Untreated control media (or PDGF-BB-stimulated control for smooth muscle cells) was evaluated on Ex vivo intimal thickness and smooth muscle cell proliferation at day 21 (p=0.004). Hydroxytyrosol (50 μM) reduced intimal thickness by 44% and smooth muscle cell proliferation by 53% (p=0.004) in ex vivo human saphenous vein rings over 21 days while preserving endothelial function.
Synapse has enriched 10 related papers. Consider them for comparative context: